Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Infectious Disease, and Exosome Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD81 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD81 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD81 Products |
| Gene Delivery | CD81 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Crucial for tetraspanin conformation. |
View CD81 Products |
| Benchmark Ab | Anti-CD81 Recombinant positive control. |
View CD81 Products |
| Validator | CD81 siRNA Set For knockdown verification. |
View CD81 Products |
| Related Target A | CD19 BCR co-receptor complex partner. |
View CD19 Products |
| Related Target B | CD21 BCR co-receptor complex partner (CR2). |
View CD21 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Conformation (Tetraspanin) | Lentivirus Premade Particles for stable cell line generation. Preserves native multi-pass structure. |
| Extracellular Loop (ECL) Specificity | Sequence Verified ECL1/ECL2 fragments, High Purity (>95%) for precise epitope mapping. |
| Lack of Controls | Clinical Benchmark Antibodies included. |
| False Positives in Exosome Assays | Validated siRNA included for specificity checks. |
Live CD81 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD81 therapeutics is intensifying, with major players shifting focus from traditional mAbs in infectious diseases (HCV) to Exosome-based Delivery Systems and Oncology. As first-generation therapies reach the clinic, the next wave of R&D is targeting bispecifics and utilizing CD81 as a scaffold for engineered exosomes in targeted drug delivery.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Exosome Therapeutics | Codiak, Evox | Targeted Delivery | Native conformation markers (Need Lentivirus for cell lines) |
| Bispecifics | Various Biotech | B-cell Malignancies | Heterodimer Validation (Need High-purity ECD) |
| mAbs | Legacy HCV Developers | Viral Infection | Epitope mapping (Need Sequence Verified ECL domains) |